Policy changes could make esketamine more affordable for treatment-resistant depression

A associated probe squad led by the LKS Faculty of Medicine of the University of Hong Kong (HKUMed), successful collaboration with The Chinese University of Hong Kong, New York University and Newcastle University, has recovered that a operation of policies and work measures could heighten the worth and affordability of esketamine nasal spray, a caller rapid-acting attraction for adults with treatment-resistant slump (TRD) successful Hong Kong.